Fluicell

Fluicell is pioneering a new paradigm in tissue engineering with its proprietary Nexocyte™ platform, which leverages twenty years of R&D and its Biopixlar bioprinting technology to create functional tissues with single-cell precision. The company is advancing a pipeline focused on tissue-based therapeutics for type 1 diabetes and complex in vitro models for cardiac toxicity and kidney disease screening. By enabling the design and production of tailored biological tissues, Fluicell aims to transform the treatment of chronic diseases and accelerate drug development for its pharmaceutical partners.

Nexocyte™ tissue production platform, centered on the Biopixlar high-resolution single-cell bioprinting technology. It enables the design and fabrication of functional biological tissues with precise cellular architecture, without bioinks, for regenerative medicine and advanced drug screening models.

Fluicell operates in the competitive fields of bioprinting, tissue engineering, and regenerative medicine. Its key differentiator is the single-cell resolution and bioink-free printing of its Biopixlar technology. Competitors range from large medical device companies and biotech firms developing cell therapies to other bioprinter manufacturers, but few offer the same level of architectural control for tissue fabrication.